Who makes PBF-509_160 mg?

PBF-509_160 mg is developed by Palobiofarma SL.

Last reviewed 2026-04-20 · How we verify

PBF-509_160 mg

Palobiofarma SL · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	PBF-509_160 mg
Sponsor	Palobiofarma SL
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PBF-509_160 mg CI brief — competitive landscape report
PBF-509_160 mg updates RSS · CI watch RSS
Palobiofarma SL portfolio CI